Chad A. Hamilton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chad A. Hamilton has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- George Larry Maxwell
Gynecologic Cancer Center of Excellence, Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA
3 shared publications - Thomas Carl Krivak
Magee-Women’s Hospital of UPMC, Division of Gynecologic Oncology, Pittsburgh PA 15213, USA
2 shared publications - Andrew Berchuck
Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA
1 shared publication - Austin Miller
Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
1 shared publication - Bunja Rungruang
Department of Obstetrics and Gynecology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
1 shared publication - Caela Miller
Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, MD, USA
1 shared publication
Latest Publications
- 1 June 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (6) , 390-392
Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer
Most patients with epithelial ovarian cancer (EOC) are diagnosed at an advanced stage, and 5-year survival is low. Initial management includes primary debulking surgery (PDS) followed by adjuvant platinum and taxane-based chemotherapy. A large number of studies have shown a survival benefit for patients with advanced EOC after PDS from both optimal debulking (P < 0.01; OS, 41 vs 77 months; P < 0.01). Patients with high preoperative disease burden (DS high) had shorter PFS and OS than did those with DS moderate or low (PFS, 15 vs 23 or 34 months [P < 0.01]; OS, 40 vs 71 or 86 months [P < 0.01], respectively). This relationship was maintained in the subset of R0 patients with PFS (18 vs 33 months; DS moderate or low: P < 0.001) and OS (50 vs 83 months; DS moderate or low: P < 0.001). Complexity score was not an independent prognostic indicator of either PFS or OS after controlling for DS, as well as performance status, age, and cell type. These data show that initial disease burden remains a significant prognostic indicator for PFS and OS despite R0. Survival is not improved by complex surgery after adjusting for confounding influences, especially residual disease.
- 1 June 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (6) , 390-392
Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer
Most patients with epithelial ovarian cancer (EOC) are diagnosed at an advanced stage, and 5-year survival is low. Initial management includes primary debulking surgery (PDS) followed by adjuvant platinum and taxane-based chemotherapy. A large number of studies have shown a survival benefit for patients with advanced EOC after PDS from both optimal debulking (P < 0.01; OS, 41 vs 77 months; P < 0.01). Patients with high preoperative disease burden (DS high) had shorter PFS and OS than did those with DS moderate or low (PFS, 15 vs 23 or 34 months [P < 0.01]; OS, 40 vs 71 or 86 months [P < 0.01], respectively). This relationship was maintained in the subset of R0 patients with PFS (18 vs 33 months; DS moderate or low: P < 0.001) and OS (50 vs 83 months; DS moderate or low: P < 0.001). Complexity score was not an independent prognostic indicator of either PFS or OS after controlling for DS, as well as performance status, age, and cell type. These data show that initial disease burden remains a significant prognostic indicator for PFS and OS despite R0. Survival is not improved by complex surgery after adjusting for confounding influences, especially residual disease.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 139
Gene Expression Analysis of Early Stage Endometrial Cancers Reveals Unique Transcripts Associated with Grade and Histology but Not Depth of Invasion
Endometrial cancer is the most common gynecologic malignancy in the United States but it remains poorly understood at the molecular level. This investigation was conducted to specifically assess whether gene expression changes underlie the clinical and pathologic factors traditionally used for determining treatment regimens in women with stage I endometrial cancer. These include the effect of tumor grade, depth of myometrial invasion and histotype. We utilized oligonucleotide microarrays to assess the transcript expression profile in epithelial glandular cells laser microdissected from 79 endometrioid and 12 serous stage I endometrial cancers with a heterogeneous distribution of grade and depth of myometrial invasion, along with 12 normal post-menopausal endometrial samples. Unsupervised multidimensional scaling analyses revealed that serous and endometrioid stage I cancers have similar transcript expression patterns when compared to normal controls where 900 transcripts were identified to be differentially expressed by at least fourfold (univariate t-test, p < 0.001) between the cancers and normal endometrium. This analysis also identified transcript expression differences between serous and endometrioid cancers and tumor grade, but no apparent differences were identified as a function of depth of myometrial invasion. Four genes were validated by quantitative PCR on an independent set of cancer and normal endometrium samples. These findings indicate that unique gene expression profiles are associated with histologic type and grade, but not myometrial invasion among early stage endometrial cancers. These data provide a comprehensive perspective on the molecular alterations associated with stage I endometrial cancer, particularly those subtypes that have the worst prognosis.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 139
Open AccessGene Expression Analysis of Early Stage Endometrial Cancers Reveals Unique Transcripts Associated with Grade and Histology but Not Depth of Invasion
Endometrial cancer is the most common gynecologic malignancy in the United States but it remains poorly understood at the molecular level. This investigation was conducted to specifically assess whether gene expression changes underlie the clinical and pathologic factors traditionally used for determining treatment regimens in women with stage I endometrial cancer. These include the effect of tumor grade, depth of myometrial invasion and histotype. We utilized oligonucleotide microarrays to assess the transcript expression profile in epithelial glandular cells laser microdissected from 79 endometrioid and 12 serous stage I endometrial cancers with a heterogeneous distribution of grade and depth of myometrial invasion, along with 12 normal post-menopausal endometrial samples. Unsupervised multidimensional scaling analyses revealed that serous and endometrioid stage I cancers have similar transcript expression patterns when compared to normal controls where 900 transcripts were identified to be differentially expressed by at least fourfold (univariate t-test, p < 0.001) between the cancers and normal endometrium. This analysis also identified transcript expression differences between serous and endometrioid cancers and tumor grade, but no apparent differences were identified as a function of depth of myometrial invasion. Four genes were validated by quantitative PCR on an independent set of cancer and normal endometrium samples. These findings indicate that unique gene expression profiles are associated with histologic type and grade, but not myometrial invasion among early stage endometrial cancers. These data provide a comprehensive perspective on the molecular alterations associated with stage I endometrial cancer, particularly those subtypes that have the worst prognosis.
- 31 December 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 123 (3) , 616
Re: Implications of upper abdominal disease in advanced ovarian cancer after surgical cytoreduction and relation with tumor biology
- 31 December 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 123 (3) , 616
Re: Implications of upper abdominal disease in advanced ovarian cancer after surgical cytoreduction and relation with tumor biology